subject: Vision Shopsters: Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape [print this page] Introduction Introduction
The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.
Scope
*Overview of Australia's socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.
*Assesses the size of Australia's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.
*Examines Australia's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.
*Quantifies Australia's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.
Highlights
Australia's health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 200708, which is the same percentage of GDP as the previous year. Australia's health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.
Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia's biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.
Reasons to Purchase
*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
*Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.
*Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.
To know more about this report & to buy a copy please visit :
